All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The first quarter of the year is not going to go down as the most memorable for blue chip public biopharmaceutical companies. March was particularly tough on them, despite a rally in the broader markets last Thursday ahead of the Easter holiday weekend.